Citations

Clear

2429 citation(s) found for "Shah, SS".

Spectrum, prevalence, and clinical correlates of PPM1D mutations in patients with clonal hematopoiesis and clonal cytopenias
Badar, Talha , Marando, Ludovica , Latorre-Crespo, Eric, Oliva, Francyess Denis, Lin, Chenyu , McCormick, Benjamin J. , Kettani, Mobachir El , Shah, Kashish, Kusne, Yael , Jamy, Omer , Diebold, Kendall , Coltoff, Alexander , Finke, Christy M. , Foran, James M. , Kharfan‐Dabaja, Mohamed A. , Fan, Yao‐Shan, Jiang, Liuyan , He, Rong , Thomas, M. , Patel, Anand , Viswanatha, D., Shah, Maleeha, Mangaonkar, Abhishek A. , Kirschner, Kristina , Al‐Kali, Aref , Gangat, Naseema, Litzow, Mark R. , Patnaik, Mrinal M. , Latorre‐Crespo, Eric , Latorre, Eric , Lin, Chenyu , El Kettani, Mobachir , Kusne, Yael N , Jamy, Omer , Kharfan-Dabaja, Mohamed A , He, Rong , Patel, Anand , Viswanatha, David, Shah, Mithun V , Saliba, Antoine N , Kirschner, Kristina , Al-Kali, Aref , Gangat, Naseema , Litzow, Mark R. , Patnaik, Mrinal , Badar, Talha , Lasho, Terra L. , Thomas, Miles, Saliba, Antoine N. , Gangat, Naseema

Mayo Clinic

Blood Advances | January 7, 2026 | Volume: 10 | Issue: 5 | Pages: 1746-1755

10.1182/bloodadvances.2025018031 | PMID 41499760 Get It

Abstract TP53 and PPM1D are key regulators of DNA damage response and repair, and somatic mutations in these genes often co-occur in hematopoietic cells, expanding under genotoxic stress. Unlike TP53 mutations, where mechanisms of progression are defined, pathways underlying clonal fitness and transformation in PPM1D mutant cells remain unclear. In collaboration with 5 academic institutions, we analyzed the clinical and molecular landscape of 337 patients with clonal hematopoiesis (CH) and clonal cytopenia of undetermined significance (CCUS) across 4 genotypes: PPM1Dmt/TP53wt (n = 170 [50%]), PPM1Dmt/TP53mt (n = 25 [7%]), TP53mt/PPM1Dwt (n = 17 [5%]), and TP53wt/PPM1Dwt (n = 125 [38%]). All PPM1D variants were truncating, located in exon 6 of the gene, with a median variant allele frequency (VAF) of 6% (range, 0.3%-64%). The PPM1Dmt/TP53mt genotype was most frequently encountered in therapy-related CH/CCUS (t-CH/t-CCUS; 80%, 66.5%, 76.5%, and 19%; P ≤ .001) and had a shorter time interval to detection from last genotoxic exposure (6.2, 5.9, 11.25, and 24.5 months; P ≤ .001) compared with PPM1Dmt/TP53wt, TP53mt/PPM1Dwt, and TP53wt/PPM1Dwt genotypes, respectively. Acknowledging the short follow-up duration, rates of malignant transformation were lower in the PPM1Dmt/TP53wt (2%) and PPM1Dmt/TP53mt (4%) groups compared with PPM1Dwt/TP53wt (12%) and PPM1Dwt/TP53mt (17%) groups (P ≤ .001), respectively. In summary, PPM1D mutations are frequently observed in t-CH/t-CCUS, with low median VAFs, and are associated with low rates of progression, even when comutated with TP53.
Cyclin D1 Overexpression With Cytoplasmic Localization Distinguishes Erdheim-Chester Disease From Reactive Histiocytic Infiltrates
Oskarsdottir, Alma, Ravindran, Aishwarya, Abeykoon, Jithma P., Bennani, Nora, Shah, Maleeha, Goyal, Gaurav , Go, Ronald S., Network, on behalf of the Histio-care, Ravindran, Aishwarya , Oskarsdottir, Alma R , Bennani, Nora N, Ravindran, Aishwarya , Koster, Matthew J. , Abeykoon, Jithma P. , Go, Ronald S. , Rech, Karen L.

Mayo Clinic

American Journal of Surgical Pathology | January 7, 2026 | Volume: 50 | Issue: 3 | Pages: 273-282

10.1097/pas.0000000000002506 | PMID 41495601 Get It

Erdheim-Chester disease (ECD) is a rare disease characterized by the accumulation of neoplastic histiocytes in various extra-nodal tissues. Tissue biopsies involved by ECD are difficult to distinguish from reactive inflammatory infiltrates given the bland appearance of the neoplastic histiocytes. Confirmation of the ECD diagnosis often relies on molecular studies to confirm BRAF V600E mutation or other activating mutations involving MAPK pathway genes. In this study, we examined the diagnostic utility of cyclin D1 and pERK as immunohistochemical markers of MAPK pathway activation in ECD compared with its histopathologic mimics. The cohort included 41 clinically confirmed ECD patients, most with known genetic alterations in MAPK pathway genes (n=38). In 3 cases no mutation was identified. 37 of 41 (90%) of ECD cases showed cyclin D1 overexpression, with frequent staining in the cytoplasm as well as the nucleus. pERK expression was observed in 32 of 39 (82%) cases. Cyclin D1 staining was negative in histopathologic mimics of ECD, apart from weak patchy staining in fat necrosis and uniform staining in a subset of cases of juvenile/adult xanthogranuloma. While not entirely sensitive or specific, in the proper clinical and radiologic context strong nuclear and cytoplasmic cyclin D1 expression within histiocytic infiltrates helps to support a diagnosis of ECD.
A Randomized, Double-Blind, Controlled, Parallel Group Study with Amustaline/Glutathione Pathogen Reduced Red Blood Cells in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections (RedeS Study): -- Protocol for a Phase 3, Randomized, C
Ayala, Edgardo F. Cartagena, Colon, Lumen Vera, Aydinok, Y., Arboleda-Osorio, Bolivar , Bracey, Arthur , Fasano, Ross M. , Yee, Marianne, Zubair, Abba, Nizzi, Frank, Shah, Sanjay, Snyder, Edward L. , Treml, Angela , Zheng, Yan, Takemoto, Clifford M., Green, Jeffrey A., Jackson, Bryon , Gniadek, Thomas J. , Bentow, Stanley, Mufti, Nina, Aydınok, Yeşim , Fasano, Ross M. , Sarode, Ravi , Pitman, John P. , Liu, Kathy , Corash, Laurence M , Benjamin, Richard J

Mayo Clinic

No container title available | December 31, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7801515/v1 Get It

Abstract Background Red blood cell (RBC) transfusion may be lifesaving, however transfusion-transmitted infections (TTI) and transfusion-associated graft-versus-host disease (TA-GVHD) still pose a threat despite current donor selection and testing requirements. Amustaline (S-303)/glutathione (GSH) pathogen reduction (PR) is designed to inactivate infectious microbes and leukocytes in RBCs. The RedeS study evaluates the safety and efficacy of amustaline/GSH PR-RBCs compared to conventional RBCs in a broad spectrum of patients requiring acute and/or repeated RBC transfusion support. Methods RedeS is a Phase 3, prospective, multi-center, randomized, double-blind, active-controlled, parallel-design study, with a 6-month extension option to evaluate patients requiring repeated transfusions including red cell exchange (RCE).Eligible subjects will be stratified according to site, baseline bleeding status and participation in the extension period. The study arms include a transfusion period of 28-days for anemia with any bleeding or non-bleeding patients or a 28-day+6-month extension for non-bleeding patients with chronic anemia requiring repeated simple transfusions, or for patients with sickle cell disease (SCD) expected to receive three RCE procedures. The study will seek to enroll 600-800 subjects in the overall safety analysis, including ~140 repeatedly-transfused subjects in the 6-month extension including up to 30 subjects receiving three RCE procedures. The primary safety endpoints are the proportion of patients with any treatment-emergent adverse events (TEAEs) related to study RBC transfusion through 28 days after the last study transfusion, and the proportion of patients with treatment-emergent antibodies with confirmed specificity to PR-RBCs. The primary efficacy endpoint is the hemoglobin (Hb) increment in subjects who are non-bleeding at baseline, adjusted for the grams of Hb transfused and averaged over multiple transfusions. With 352 evaluable transfused non-bleeding subjects (176 per treatment group) from either arm, the study will have 80% power to demonstrate non-inferiority, defined as a Hb increment treatment difference of no more than 15% of the Control group mean, assuming a Control arm coefficient of variation of 50%. Discussion RedeS will characterize the safety of amustaline/GSH PR-RBCs and is designed to demonstrate the non-inferiority of PR-RBCs to conventional RBCs with respect to Hb increment, a common pragmatic clinical assessment of RBC transfusion effectiveness.
FP3.2 The Impact of Femoral Version on the Outcomes of Hip Arthroscopic Surgery for Femoroacetabular Impingement: Results of a Multicenter Prospective Cohort Study
Nepple, Jeffrey, Shah, Vivek P. , Westermann, Robert, Spiker, Andrea M. , Levy, Bruce, Yen, Yi-Meng, Group, ANCHOR Study, Clohisy, John C, Nepple, Jeffrey J. , Westermann, Robert W. , Krych, Aaron J. , Yen, Yi‐Meng , Group, ANCHOR Study, Clohisy, John C.

Mayo Clinic

Journal of Hip Preservation Surgery | December 22, 2025 | Volume: 12 | Issue: Supplement_2 | Pages: ii5-ii6

10.1093/jhps/hnaf069.015 Get It

Abstract Background Femoral version plays a critical role in pre-arthritic hip pain, particularly in femoroacetabular impingement (FAI). Variations in femoral version may contribute to hip instability or impingement. This study examines the outcomes of hip arthroscopy for FAI across different femoral version groups. Methods A prospective multicenter cohort of 677 FAI patients undergoing primary hip arthroscopy was collected, with 603 patients in this study based on recorded femoral version. Inclusion criteria were patients aged 14-45 years with idiopathic FAI, while previous ipsilateral hip procedures, associated disorders, or Tönnis 2 or greater osteoarthritis were excluded. Femoral version was measured on low-dose computed tomography (CT) utilizing the Yoshioka oblique method and categorized into five subgroups: <5°, 6°-15°, 16°-25°, 26°-35°, 35°+. Patient-reported outcomes (PROs) were obtained at minimum one-year follow-up. The modified Harris hip score (mHHS) was assessed relative to minimal clinically important difference (MCID) of 8 and patient acceptable symptom state (PASS) of 74. Additional PROs included HOOS Pain and Sports/Recreation subscores and iHOT-12 score. Composite failure was defined as reoperation for persistent symptoms or failure to achieve either the mHHS MCID or PASS. Results Males had statistically lower femoral version than females (14.0 vs 18.0; p<0.001). In females, 38.0% had a femoral version of 16°-25°, 17.9% between 26°-35°, and 3.6% greater than 35°, compared to 27.6%, 9.2%, and 1.8% in males, respectively (all p<0.001). Increased or decreased femoral versions appear to have similar outcomes to normal version. The mildly increased femoral anteversion groups of 16°-25° and 26°-35° demonstrated the best outcomes with changes in HOOS pain and sports subscores being significantly higher. Severely increased femoral anteversion, >35°, only present in 2.8% of patients, demonstrated a higher composite failure rate (15.4%) compared to moderately increased, 26°-35°, femoral version (3.1%). The decreased femoral version group, ≤5°, had a composite failure of 10.4% compared to normal femoral version, 16°-25° (10.2%). Conclusions The general anatomy differences between males and females lends males to be more in retroversion while females tend to be more anteverted. Overall, outcomes did not seem to differ between increased or decreased femoral versions but were superior at mildly increased femoral versions.
CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients
Gangat, Naseema, Fathima, Saubia , Rokach, Lior , Ghosoun, Nour, Rezasoltani, Mahsa , Ilyas, Rimal, Alsugair, Ali, McCullough, Kristen , Abdelmagid, Maymona, Al‐Kali, Aref , Alkhateeb, H., Begna, Kebede H. , Mangaonkar, Abhishek, Matin, Aasiya, Hefazi, Mehrdad T., LITZOW, Mark R., Shah, Maleeha, Patnaik, Mrinal M. , Pardanani, Animesh, Foran, James M. , Palmer, Jeanne , Punwani, Nathan , Sproat, Lisa, Khera, Nandita , Tefferi, Ayalew, McCullough, Kristen B , Fathima, Saubia , Ghosoun, Nour, Ilyas, Rimal, Alkhateeb, Hassan B. , Mangaonkar, Abhishek A. , Matin, Aasiya , Saliba, Antoine N. , Hefazi, Mehrdad , Litzow, Mark R. , Hogan, William J , Shah, Mithun V , Pardanani, Animesh , Badar, Talha , Murthy, Hemant S. , Sproat, Lisa, Yi, Cecilia Arana , Tefferi, Ayalew , Gangat, Naseema

Mayo Clinic

No container title available | December 22, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-8233179/v1 Get It

Abstract The comparative value of liposomal cytarabine/daunorubicin (CPX-351) versus venetoclax plus a hypomethylating agent (Ven-HMA) in the frontline treatment of older adults with primary ( de novo ) or secondary acute myeloid leukemia (AML) remains uncertain. In the current study, we retrospectively examined outcomes of 600 patients with newly diagnosed AML treated with CPX-351 (N = 112) or Ven-HMA (N = 488). AML subtypes included de novo (46%), post-myelodysplastic syndrome (MDS) (19%), post-myeloproliferative neoplasm (MPN) (12%), post-MDS/MPN (6%), therapy-related (17%) and AML with myelodysplasia-related genetic abnormalities (AML-MR; 46%). Patients receiving CPX-351 were younger (median 65 vs. 73 years; p < 0.01), predominantly female (50% vs. 38%; p = 0.02), more likely to have secondary AML (68% vs. 51%; p < 0.01), and less likely to harbor NPM1 MUT (5% vs. 12%; p = 0.02). Rates of complete response with or without count recovery (CR/CRi) were comparable between CPX-351 and Ven-HMA (55% vs. 60%; p = 0.30), including in AML-MR (60% vs. 63%; p = 0.70). Ven-HMA use was associated with fewer infectious complications (62% vs. 83%; p < 0.01) and yielded higher CR/CRi rates in males (60% vs. 45%; p = 0.04), de novo AML (68% vs. 50%; p = 0.03), and in the presence of STAG2 MUT (86% vs. 44%; p = 0.02), or CEBPA MUT (88% vs. 50%; p = 0.03). Overall survival censored for transplant, was similar (median 10 vs. 13 months; p = 0.90), with Ven-HMA being superior in post-MDS AML (median 12 vs. 7 months; p = 0.02) and CPX-351 in the presence of SF3B1 MUT (not reached vs. 14 months; p < 0.01). Our findings suggest that Ven-HMA is as effective and less toxic than CPX-351 in newly diagnosed AML, including AML-MR, despite selection of younger, fitter patients for CPX-351.
Medical management of inflammatory bowel diseases
Limdi, Jimmy K. , Shapiro, Jason M. , Shah, Samir A. , Hashash, Jana G.

Mayo Clinic

BMJ | December 19, 2025 | Volume: 391 | Issue: No issue available | Pages: e079050

10.1136/bmj-2025-079050 | PMID 41419296 Get It

Abstract Inflammatory bowel diseases (IBD), comprising Crohn’s disease and ulcerative colitis, are chronic, inflammatory, immune mediated, relapsing-remitting conditions of the gastrointestinal tract with multidimensional and often negative effects on patients’ quality of life. The global burden of IBD is increasing and is forecast to affect 1% of the population in early industrialized nations over the next 10 years. Advances in our understanding of the causes and pathogenesis of IBD in the past three decades have translated into new treatments that modulate the immune inflammatory cascade. Modern goals of treatment are clinical remission through assessment of patient reported outcomes and deep remission defined as mucosal healing on colonoscopy or imaging. Achieving both clinical and deep remission affords patients a better long term prognosis and quality of life. This review summarizes the latest evidence on IBD diagnosis, staging, and prognosis, with a detailed focus on current treatments.
RETRACTED: Patel et al. Effect Comparison of E-Cigarette and Traditional Smoking and Association with Stroke—A Cross-Sectional Study of NHANES. Neurol. Int. 2022, 14, 441–452
Patel, Urvish , Patel, Neel , Khurana, Mahika , Parulekar, Akshada, Patel, Amrapali , Ortíz, Juan Fernando , Patel, Rutul , Urhoghide, Eseosa, Mistry, Anuja, Bhriguvanshi, Arpita, Abdulqader, Mohammed Ali, Mehta, Neev , Arumaithurai, Kogulavadanan , Shah, Shamik , Patel, Urvish K

Mayo Clinic

Neurology International | December 18, 2025 | Volume: 17 | Issue: 12 | Pages: 207

10.3390/neurolint17120207 | PMID 41410513 Get It

The journal retracts the article, “Effect Comparison of E-Cigarette and Traditional Smoking and Association with Stroke—A Cross-Sectional Study of NHANES” [...]
PD-1–based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma
Desai, Sanjal H. , Moskowitz, Alison J. , Pederson, Levi , Geyer, Susan, Ganesan, Nivetha , Chang, Tiffany , Othman, Tamer , Falade, Ayo , Ng, Lay She , Baron, Margaret Kelsey , Ong, Shin Yeu , Yoon, Kevin, Ansell, Stephen M. , Armand, Philippe , Iyengar, Siddharth , Micallef, Ivana N. , Herrera, Alex F. , Pederson, Levi D , Chang, Tiffany , Othman, Tamer , Falade, Ayo S , Shah, Gunjan L , Sumransub, Nuttavut , Baron, Kelsey , Ong, Shin Yeu , Micallef, Ivana, Stuver, Robert , Herrera, Alex F , Mei, Matthew , Desai, Sanjal , Merryman, Reid W. , Shah, Harsh, Shah, Gunjan L. , Durani, Urshila , Stuver, Robert , Mei, Matthew

Mayo Clinic

Blood | December 17, 2025 | Volume: 147 | Issue: 10 | Pages: 1125-1134

10.1182/blood.2025030151 | PMID 41405496 Get It

Abstract Combination therapy incorporating programmed cell death protein 1 (PD-1) blockade results in unprecedented response rates in both frontline and relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). Previous retrospective studies have suggested benefit for PD-1 blockade before autologous stem cell transplant (ASCT) but included few patients receiving PD-1 blockade with cytotoxic chemotherapy. To explore the impact of anti–PD-1 based salvage on outcomes for patients with R/R cHL, we retrospectively reviewed 1280 patients with R/R cHL who underwent ASCT from 2010 to 2022 at 6 transplant centers, none of whom received PD-1 blockade as part of frontline therapy. Overall, 25% received a PD-1 inhibitor at any point before ASCT (10% in conjunction with chemotherapy), 28% received salvage brentuximab vedotin (BV) without PD-1 blockade, and the rest received salvage chemotherapy alone. Patients who received PD-1 inhibitors at any point before ASCT had a significantly higher 2-year progression-free survival than those who received BV without PD-1 inhibitors or patients receiving chemotherapy alone (88.2%, 70.2%, and 67.4%, respectively; P&lt; .0001). When restricted to patients in complete response before ASCT, the benefit of PD-1 blockade remained significant. PD-1 blockade before ASCT is independently associated with superior post-ASCT outcomes and patients proceeding to ASCT should be treated with PD-1–based salvage.
Blast Clearance Dynamics and Time to Response Across IDH1‐ and IDH2 ‐Mutated AML
Najeeb, Mohamad Sheikh, Alkabbani, Oudai, He, Rong , Matin, Aasiya , Mangaonkar, A., Patnaik, Mrinal M. , Gangat, Naseema , Litzow, Mark R. , Yi, Cecila Y. Arana, Foran, James M. , Begna, Kebede H. , Al‐Kali, Aref , Mangaonkar, Abishek, Jevremović, Dragan , Greipp, Patricia T. , Hefazi, Mehrdad , Mangaonkar, Abhishek A. , Hogan, William J. , Alkhateeb, Hassan B. , Shah, Meera , Kewan, Tariq Zuheir , Saliba, Antoine N.

Mayo Clinic

eJHaem | December 15, 2025 | Volume: 6 | Issue: 6 | Pages: No page available

10.1002/jha2.70204 | PMID 41404482 Get It

ABSTRACT Background IDH mutations are found in 15%–20% of acute myeloid leukemia (AML). Recent evidence suggests that IDH mutation subtypes may respond differently to intensive chemotherapy. We evaluated blast clearance patterns, remission outcomes, and overall survival (OS) in AML patients with IDH2 R140, IDH2 R172, and IDH1 R132 mutations to assess differences in treatment response. Methods We retrospectively reviewed AML patients diagnosed at Mayo Clinic, Rochester (2016–2023) with NGS data and treated with intensive chemotherapy (7+3 or CPX‐351). Bone marrow blasts were assessed at diagnosis, mid‐induction, and end‐of‐cycle; blast clearance was defined as < 5%. Composite remission (CRc) included CR/CRi per ELN 2022. IDH2 responders were classified as early (after Cycle 1) or late (≥ 2 cycles). Blast reduction was calculated as log 10 (diagnosis blasts/end‐induction blasts) and normalized per day. OS was measured from diagnosis. Results Among 381 patients, 31 had IDH2 mutations (23 R140, 8 R172) and eight had IDH1 R132. Baseline blasts were similar. Mid‐cycle blasts were lower in R140 versus R172 (4% vs. 10%), with higher clearance (68% vs. 38%). End‐induction blasts were lower in R140 versus R172 (2% vs. 4%) with higher clearance (100% vs. 75%). IDH1 and IDH2 showed similar clearance patterns. Log 10 analyses showed deeper and faster blast reduction in R140 versus R172, with comparable kinetics between IDH1 and IDH2 . OS did not differ across subtypes. Early CRc in IDH2 ‐mutated patients was associated with numerically longer OS. Conclusion IDH2 R140 demonstrated faster blast clearance than R172, while remission and survival were similar across IDH subtypes. Trial Registration : The authors have confirmed clinical trial registration is not needed for this submission.